Source link : https://www.newshealth.biz/health-news/new-standard-for-newly-diagnosed-pediatric-b-cell-acute-lymphoblastic-leukemia/
SAN DIEGO — Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager blinatumomab (Blincyto) in addition to chemotherapy, according to a randomized trial reported here. Median disease-free survival (DFS) at 3 years improved from 87.9% with chemotherapy alone to 96.0% with the […]
Author : News Health
Publish date : 2024-12-07 15:00:00
Copyright for syndicated content belongs to the linked Source.
Categories